How big is the Global RNA-interference (RNAi) Market?

The Global RNA-interference (RNAi) Market size is expected to reach USD 1.36 billion in 2024 and grow at a CAGR of 16.29% to reach USD 2.90 billion by 2029. Read More

What is the current Global RNA-interference (RNAi) Market size?

In 2024, the Global RNA-interference (RNAi) Market size is expected to reach USD 1.36 billion. Read More

Who are the key players in Global RNA-interference (RNAi) Market?

Alnylam Pharmaceuticals, Silence Therapeutics PLC, Arrowhead Pharmaceuticals, Inc., Thermo Fisher Scientific Inc and Dicerna Pharmaceuticals (Novo Nordisk A/S) are the major companies operating in the Global RNA-interference (RNAi) Market. Read More

Which is the fastest growing region in Global RNA-interference (RNAi) Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029). Read More

Which region has the biggest share in Global RNA-interference (RNAi) Market?

In 2024, the North America accounts for the largest market share in Global RNA-interference (RNAi) Market. Read More

What years does this Global RNA-interference (RNAi) Market cover, and what was the market size in 2023?

In 2023, the Global RNA-interference (RNAi) Market size was estimated at USD 1.17 billion. The report covers the Global RNA-interference (RNAi) Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global RNA-interference (RNAi) Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

Global RNA-interference (RNAi) Market Share

Statistics for the 2023 & 2024 Global RNA-interference (RNAi) market share, created by Mordor Intelligence™ Industry Reports. Global RNA-interference (RNAi) share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Market Share of Global RNA-interference (RNAi) Industry

The RNA-interference (RNAi) market is highly competitive and consists of a few major players. Companies like Alnylam Pharmaceuticals, Arrowhead, Dicerna Pharmaceuticals (Novo Nordisk A/S), Thermofisher Scientific, Silence Therapeutics PLC, among others, hold a substantial market share in the RNA-interference (RNAi) market.